{"title":"Review Questions","authors":"","doi":"10.1055/s-2005-916171","DOIUrl":null,"url":null,"abstract":"3. In studies comparing ximelagatran and warfarin in stroke prevention and treatment of venous thromboembolism: A. the two agents showed similar antithrombotic efficacy and rates of bleeding B. the antithrombotic efficacy of ximelagatran was superior to warfarin but there were also more major bleedings C. ximelagatran was less effective than warfarin, but was associated with less bleeding D. antithrombotic efficacy was better and bleeding rates were lower with ximelagatran as compared with warfarin E. the antithrombotic effect of ximelagatran was non-inferior to warfarin, with significantly fewer major and minor bleedings with ximelagatran","PeriodicalId":87139,"journal":{"name":"Seminars in vascular medicine","volume":"5 1","pages":"C1 - C4"},"PeriodicalIF":0.0000,"publicationDate":"2005-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1055/s-2005-916171","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Seminars in vascular medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1055/s-2005-916171","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
3. In studies comparing ximelagatran and warfarin in stroke prevention and treatment of venous thromboembolism: A. the two agents showed similar antithrombotic efficacy and rates of bleeding B. the antithrombotic efficacy of ximelagatran was superior to warfarin but there were also more major bleedings C. ximelagatran was less effective than warfarin, but was associated with less bleeding D. antithrombotic efficacy was better and bleeding rates were lower with ximelagatran as compared with warfarin E. the antithrombotic effect of ximelagatran was non-inferior to warfarin, with significantly fewer major and minor bleedings with ximelagatran